Loading stock data…
CTOR
$0.99+0.08 (+9.27%)
Citius Oncology, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Citius Oncology, Inc. in the Healthcare sector is trading at $0.99. Wall Street consensus targets $6.00 (1 analysts), implying a +507.9% move over the next 12 months. The stock is currently near its 52-week low of $0.49, remaining 24.7% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +507.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$0.99
Potential Downside
0%
Whystock Fair Value$0.99
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cuta...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$82.10M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
3.43
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-40.46%
Volume
Today's trading volume
121,671
Recent News
Citius raises $36.5m for Lymphir commercialisation
The capital includes a $25m term loan and a warrant exercise agreement expected to yield $11.5m.
Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR)
Citius Oncology, Inc. ( NASDAQ:CTOR ) is possibly approaching a major achievement in its business, so we would like to...
Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR
Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the stocks that should double in 3 years. On February 13, Citius Pharmaceuticals officially transitioned into a revenue-generating company following the December 2025 commercial launch of LYMPHIR. For FQ1 2026, the company reported $3.9 million in consolidated revenue, reflecting initial sales through a nationwide network of specialty distributors. […]
Citius Oncology (CTOR) Expands LYMPHIR Distribution to Europe Through Exclusive Agreement With Uniphar
Citius Oncology Inc. (NASDAQ:CTOR) is one of the most undervalued penny stocks to buy right now. On February 11, Citius Oncology entered into an exclusive distribution agreement with Uniphar to expand the availability of its oncology treatment, LYMPHIR, throughout Western and Eastern Europe. This partnership marked Citius Oncology’s third major international agreement, following similar arrangements […]
Citius Oncology and Uniphar sign European distribution deal for Lymphir
Uniphar will act as the exclusive distributor for Lymphir in designated European territories.